Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Specific granules

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    62 result(s) found for: Specific granules. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2020-001961-34 Sponsor Protocol Number: RDG-1/PBC Start Date*: 2021-02-02
    Sponsor Name:Dr. Falk Pharma GmbH
    Full Title: Double-blind, randomised, placebo-controlled, phase II dose-finding study comparing different doses of RhuDex granules with placebo in the treatment of primary biliary cholangitis
    Medical condition: Primary biliary cholangitis
    Disease: Version SOC Term Classification Code Term Level
    21.0 10019805 - Hepatobiliary disorders 10080429 Primary biliary cholangitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) HU (Prematurely Ended) SK (Prematurely Ended) NL (Prematurely Ended) BE (Completed) PL (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-001474-24 Sponsor Protocol Number: 3001B3–335-WW Start Date*: 2006-08-07
    Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc, Clinical Research and Development
    Full Title: A MULTICENTER, OPEN LABEL SAFETY STUDY OF 2 DOSES OF PANTOPRAZOLE SODIUM ENTERIC-COATED SPHEROID SUSPENSION IN INFANTS AGED LESS THAN 12 MONTHS WITH PRESUMED GERD
    Medical condition: INFANTS AGED LESS THAN 12 MONTHS WITH PRESUMED GERD
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) IT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2006-004159-39 Sponsor Protocol Number: BUC-60/COC Start Date*: 2007-03-15
    Sponsor Name:Dr. Falk Pharma GmbH
    Full Title: Double-blind, double-dummy, randomised, placebo-controlled, multi-centre phase III clinical study on the efficacy and tolerability of budesonide capsules vs. mesalazine granules vs. placebo for pat...
    Medical condition: Collagenous colitis
    Disease: Version SOC Term Classification Code Term Level
    14.0 10017947 - Gastrointestinal disorders 10048928 Colitis collagenous PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) LT (Completed) DK (Completed) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-001132-45 Sponsor Protocol Number: 3001B3-333-WW Start Date*: 2006-08-07
    Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc, Clinical Research and Development
    Full Title: A MULTICENTER, RANDOMIZED, OPEN LABEL, SINGLE AND MULTIPLE DOSE STUDY OF THE PHARMACOKINETICS AND PHARMACODYNAMICS OF 2 DOSE LEVELS OF PANTOPRAZOLE SODIUM ENTERIC-COATED SPHEROID SUSPENSION IN INF...
    Medical condition: INFANTS AGED 1 THROUGH 11 MONTHS WITH PRESUMED GERD
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) IT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2006-001473-24 Sponsor Protocol Number: 3001B3-331-WW Start Date*: 2007-01-16
    Sponsor Name:Wyeth Research, Clinical Research and Development, Division of Wyeth Pharmaceuticals Inc.
    Full Title: A MULTICENTER, OPEN-LABEL PHARMACOKINETIC, PHARMACODYNAMIC, CLINICAL SYMPTOMS, AND SAFETY STUDY OF PANTOPRAZOLE DELAYED-RELEASED GRANULES ADMINISTERED AS A SUSPENSION IN NEONATES AND PRETERM INFANT...
    Medical condition: Clinical diagnosis of gastroesophagal reflux disease (GERD) in neonates and preterm infants
    Disease:
    Population Age: Preterm newborn infants, Newborns, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed) FR (Completed) IT (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2018-004154-25 Sponsor Protocol Number: CLCZ696B2319E1 Start Date*: Information not available in EudraCT
    Sponsor Name:Novartis Pharma AG
    Full Title: A multicenter study to evaluate long-term safety and tolerability of open label sacubitril/valsartan in pediatric patients with heart failure due to systemic left ventricle systolic dysfunction wh...
    Medical condition: Pediatric heart failure : Patients (≥ 13 months) with HF due to systemic left ventricular systolic dysfunction. [Note: All patients per protocol for the core study CLCZ696B2319 (PANORAMA-HF) ...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10019279 Heart failure LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: PL (Completed) FR (Completed) BG (Completed) PT (Completed) CZ (Completed) ES (Ongoing) HU (Completed) HR (Completed) DE (Completed) AT (Completed) IT (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2006-003615-40 Sponsor Protocol Number: NBS-C03-OP Start Date*: 2006-10-10
    Sponsor Name:Osteologix A/S
    Full Title: A dose-response study with stronitum malonate in postmenopausal women. 12 week, multinational, double-blind, randomised, 5 arms, parallel group placebo controlled, open label active controlled, ph...
    Medical condition: postmenopausal osteoporosis
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Completed) GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000278-13 Sponsor Protocol Number: P16-07/BP052 Start Date*: Information not available in EudraCT
    Sponsor Name:BIOPROJET PHARMA
    Full Title: Palatability testing in children of a new paediatric formulation of Racecadotril as oral suspension strawberry-flavored administered via an oral graduated syringe compared to the current formulatio...
    Medical condition: Young healthy volunteers (7-12 years)
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004856 10055955 Acute diarrhoea LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2013-004739-55 Sponsor Protocol Number: CICL670F2202 Start Date*: 2015-09-18
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, open-label, multicenter, two arm, phase II study to evaluate treatment compliance, efficacy and safety of an improved deferasirox formulation (granules) in pediatric patients with iro...
    Medical condition: transfusion-dependent anemia requiring chelation therapy due to iron overload
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10074295 Transfusion dependent anemia LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed) BG (Completed) FR (Completed) HU (Completed) DK (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-003176-13 Sponsor Protocol Number: 67133 Start Date*: 2019-02-18
    Sponsor Name:Maastricht University
    Full Title: Lowering Branched-Chain Amino Acids as a New Strategy to Treat Diabetes
    Medical condition: type 2 diabetes
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-003591-37 Sponsor Protocol Number: SPON846-10 Start Date*: 2012-09-03
    Sponsor Name:Cardiff University
    Full Title: Children with Eczema Antibiotic Management Study (CREAM)
    Medical condition: Atopic Eczema
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10003641 Atopic eczema LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-003300-31 Sponsor Protocol Number: 20159460(c) Start Date*: 2017-06-13
    Sponsor Name:Hellenic Society for the Study of Bone Metabolism
    Full Title: Evaluation of the efficacy of Denosumab in adult patients with Langerhans Cell Histiocytosis (LCH) : a multiple-site, single arm, open label Clinical Trial.
    Medical condition: Langerhans Cell Histiocytosis (LCH) is a rare disease of unknown etiology with variable clinical course exhibiting both neoplastic and inflammatory features. It is characterized by the accumulatio...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10069698 Langerhans' cell histiocytosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-001663-23 Sponsor Protocol Number: CAP01-2013 Start Date*: 2013-09-02
    Sponsor Name:FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO MILANO
    Full Title: Clinical and immunomodulatory effects of antibiotic therapy + pidotimod versus antibiotic therapy alone in patients with community-acquired pneumonia (CAP)
    Medical condition: Community acquired pneumonia
    Disease: Version SOC Term Classification Code Term Level
    16.0 10021881 - Infections and infestations 10060946 Pneumonia bacterial PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-003792-19 Sponsor Protocol Number: FOS-PROST-001 Start Date*: 2021-03-04
    Sponsor Name:Hospital Universitari Mutua Terrassa
    Full Title: Fosfomycin as an oral alternative treatment for acute bacterial prostatitis due to multi-drug resistant Escherichia coli. Pilot study
    Medical condition: Acute bacterial prostatitis due to multi-drug resistant Escherichia coli
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-004426-24 Sponsor Protocol Number: TREAT-LMNA Start Date*: 2020-07-06
    Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
    Full Title: Deflazacort TREATment in LMNA related congenital muscular dystrophy: study of clinical effectiveness and search for reliable biomarkers.
    Medical condition: Congenital Muscolar distrophy LMNA related
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10003718 Atrophy skeletal muscle LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-001223-49 Sponsor Protocol Number: PTC124-GD-041DMD Start Date*: 2018-01-16
    Sponsor Name:PTC Therapeutics, Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Ataluren in Patients with Nonsense Mutation Duchenne Muscular Dystrophy and Open-Label Extension
    Medical condition: Nonsense Mutation Duchenne Muscular Dystrophy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10013801 Duchenne muscular dystrophy PT
    Population Age: Children, Adolescents, Under 18 Gender: Male
    Trial protocol: BG (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-003579-36 Sponsor Protocol Number: BAY73-4506/15906 Start Date*: 2018-01-15
    Sponsor Name:Bayer HealthCare AG
    Full Title: A multi-center, open-label, non-randomized, phase I dose escalation study of regorafenib (BAY 73-4506) in pediatric subjects with solid malignant tumors that are recurrent or refractory to standard...
    Medical condition: Pediatric patients with solid malignant tumors that are recurrent or refractory to standard therapy.
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed) GB (Completed) FR (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2018-000515-24 Sponsor Protocol Number: RG_17-247 Start Date*: Information not available in EudraCT
    Sponsor Name:University of Birmingham
    Full Title: FaR-RMS: An overarching study for children and adults with Frontline and Relapsed RhabdoMyoSarcoma
    Medical condition: Rhabdomyosarcoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10039022 Rhabdomyosarcoma PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Trial now transitioned) NO (Trial now transitioned) GB (GB - no longer in EU/EEA) NL (Trial now transitioned) DK (Trial now transitioned) SI (Trial now transitioned) GR (Trial now transitioned) CZ (Trial now transitioned) IT (Trial now transitioned) FR (Trial now transitioned) SE (Trial now transitioned) AT (Trial now transitioned) BE (Trial now transitioned) FI (Trial now transitioned) DE (Trial now transitioned) PT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-003391-37 Sponsor Protocol Number: Scil-MD05-C01 Start Date*: 2005-12-05
    Sponsor Name:Scil Technology GmbH
    Full Title: Pilot Study on Safety and explorative Efficacy of MD05 in Comparison with the Medical Device Beta-TCP Mixed with Autogenous Bone Material in Patients Undergoing Two-Stage Unilateral Maxillary Sinus...
    Medical condition: Requirement of two-stage unilateral maxillary sinus floor augmentation in case of insufficient bone height in the area of the posterior maxilla, prior to insertion of dental implants.
    Disease: Version SOC Term Classification Code Term Level
    8.0 10061257 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-005883-25 Sponsor Protocol Number: Scil-MD05-C02 Start Date*: 2007-04-25
    Sponsor Name:Scil Technology GmbH
    Full Title: Pilot Study on Safety and Explorative Efficacy of MD05 in Comparison with Open Flap Debridement in Patients Undergoing Periodontal Surgery to Treat Deep Intrabony Defects
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    8.1 10034536 Periodontal disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 14 15:43:34 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA